Enhanced surface attachment of protein-type targeting ligands to poly(lactide-co-glycolide) nanoparticles using variable expression of polymeric acid functionality

Journal of Biomedical Materials Research - Part A

Volumn 87, Issue 4, 2008, Pages 873-884

  McCarron, Paul A ^a   Marouf, Waleed M ^b   Donnelly, Ryan F ^a   Scott, Chris ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b HIKMA PHARMACEUTICALS   (Jordan)

Author keywords

Bovine serum albumin; Conjugation; Nanoparticle; Poly(lactide co glycolide); Polyclonal antibody

Indexed keywords

ABS RESINS; ACIDS; BODY FLUIDS; CHEMICAL ACTIVATION; CONTROLLED DRUG DELIVERY; FUNCTIONAL GROUPS; FUNCTIONAL POLYMERS; MAGNESIUM PRINTING PLATES; NANOPARTICLES; NANOSTRUCTURED MATERIALS; NANOSTRUCTURES; ORGANIC POLYMERS; STABILIZATION;

BOVINE SERUM ALBUMIN; BOVINE SERUM ALBUMINS; CARBODIIMIDE CHEMISTRIES; CARBOXYL GROUPS; CELECOXIB; COMPONENT PARTS; CONJUGATION; DRUG RELEASE STUDIES; DRUG RELEASES; ENHANCED SURFACES; GLYCOLIDE; LACTIDE; MODEL DRUGS; POLY(LACTIDE-CO-GLYCOLIDE); POLY(VINYL ALCOHOL); POLYCLONAL ANTIBODIES; POLYCLONAL ANTIBODY; POLYMERIC ACIDS; STERIC STABILIZATIONS; SUSTAINED RELEASES;

NUCLEAR PROPULSION;

ACID; CARBOXYL GROUP; CELECOXIB; CYANAMIDE; NANOPARTICLE; POLYCLONAL ANTIBODY; POLYGLACTIN; POLYMERIC ACID; POLYVINYL ALCOHOL; RESOMER; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DENSITY; DRUG CONJUGATION; DRUG STABILITY; ENCAPSULATION; MOLECULAR WEIGHT; PROTEIN TARGETING; SUSTAINED DRUG RELEASE;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BIOCOMPATIBLE MATERIALS; CATTLE; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; DRUG STABILITY; HUMANS; LACTIC ACID; LIGANDS; MATERIALS TESTING; MOLECULAR STRUCTURE; MOLECULAR WEIGHT; NANOPARTICLES; POLYGLYCOLIC ACID; POLYMERS; PYRAZOLES; SULFONAMIDES; SURFACE PROPERTIES;

EID: 56749163384     PISSN: 15493296     EISSN: 15524965     Source Type: Journal    
DOI: 10.1002/jbm.a.31835     Document Type: Article

References (45)

1. Emerich DF, Snodgrass P, Lafreniere D, Dean RL, Salzberg H, Marsh J, Perdomo B, Arastu M, Winn SR, Bartus RT. Sustained release chemotherapeutic microspheres provide superior efficacy over systemic therapy and local bolus infusions. Pharm Res 2002;19:1052-1060.
2. Lamprecht A, Ubrich N, Yamamoto H, Schafer U, Takeuchi H, Maincent P, Kawashima Y, Lehr CM. Biodegradable nanoparticles for targeted drug delivery in treatment of inflammatory bowel disease. J Pharmacol Exp Ther 2001;299:775-781.
3. Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: The key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul 2001;41:189-207.
4. Sahoo SK, Panyam J, Prabha S, Labhasetwar V. Residual polyvinyl alcohol associated with poly (D,L-lactide-co-glycolide) nanoparticles affects their physical properties and cellular uptake. J Control Rel 2002;82:105-114.
5. Allen TM, Cullis PR. Drug delivery systems: Entering the mainstream. Science 2004;303:1818-1822.
6. Krause HJ, Schwarz A, Rohdewald P. Polylactic acid nanoparticles, a colloidal drug delivery system for lipophilic drugs. Int J Pharm 1985;27:145-155.
7. Allemann E, Leroux JC, Gurny R, Doelker E. In vitro extended-release properties of drug-loaded poly(D,L-lactic acid) nanoparticles produced by a salting-out procedure. Pharm Res 1993;10:1732-1737.
8. Woodley JF. Lectins for gastrointestinal targeting-15 years on. J Drug Target 2000;7:325-333.
9. Li Y, Pei Y, Zhang X, Gu Z, Zhou Z, Yuan W, Zhou J, Zhu J, Gao X. PEGylated PLGA nanoparticles as protein carriers: Synthesis, preparation and biodistribution in rats. J Control Rel 2001;71:203-211.
10. Nishioka Y, Yoshino H. Lymphatic targeting with nanoparticulate system. Adv Drug Deliv Rev 2001;47:55-64.
11. Fahmy TM, Samstein RM, Harness CC, Mark Saltzman W. Surface modification of biodegradable polyesters with fatty acid conjugates for improved drug targeting. Biomaterials 2005;26:5727-5736.
12. Cummings J, McArdle CS. Studies on the in vivo disposition of adriamycin in human tumours which exhibit different responses to the drug. Br J Cancer 1986;53:835-838.
13. Goren D, Horowitz AT, Tzemach D, Tarshish M, Zalipsky S, Gabizon A. Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump. Clin Cancer Res 2000;6:1949-1957.
14. Weitman SD, Weinberg AG, Coney LR, Zurawski VR, Jennings DS, Kamen BA. Cellular localization of the folate receptor: Potential role in drug toxicity and folate homeostasis. Cancer Res 1992;52:6708-6711.
15. Lee RJ, Low PS. Delivery of liposomes into cultured KB cells via folate receptor-mediated endocytosis. J Biol Chem 1994;269:3198-3204.
16. Gulyaev AE, Gelperina SE, Skidan IN, Antropov AS, Kivman GY, Kreuter J. Significant transport of doxorubicin into the brain with polysorbate 80-coated nanoparticles. Pharm Res 1999;16:1564-1569.
17. Steiniger SC, Kreuter J, Khalansky AS, Skidan IN, Bobruskin AI, Smirnova ZS, Severin SE, Uhl R, Kock M, Geiger KD, Gelperina SE. Chemotherapy of glioblastoma in rats using doxorubicin-loaded nanoparticles. Int J Cancer 2004;109:759-767.
18. Cho CS, Cho KY, Park IK, Kim SH, Sasagawa T, Uchiyama M, Akaike T. Receptor-mediated delivery of all trans-retinoic acid to hepatocyte using poly(L-lactic acid) nanoparticles coated with galactose-carrying polystyrene. J Control Rel 2001;77:7-15.
19. Farokhzad OC, Jon S, Khademhosseini A, Tran TN, Lavan DA, Langer R. Nanoparticle-aptamer bioconjugates: A new approach for targeting prostate cancer cells. Cancer Res 2004;64:7668-7672.
20. Mo Y, Lim LY. Preparation and in vitro anticancer activity of wheat germ agglutinin (WGA)-conjugated PLGA nanoparticles loaded with paclitaxel and isopropyl myristate. J Control Rel 2005;107:30-42.
21. Faraasen S, Voros J, Csucs G, Textor M, Merkle HP, Walter E. Ligand-specific targeting of microspheres to phagocytes by surface modification with poly(L-lysine)-grafted poly(ethylene glycol) conjugate. Pharm Res 2003;20:237-246.
22. Dinauer N, Balthasar S, Weber C, Kreuter J, Langer K, von Briesen H. Selective targeting of antibody-conjugated nanoparticles to leukemic cells and primary T-lymphocytes. Biomaterials 2005;26:5898-5906.
23. Yoo HS, Park TG. Folate receptor targeted biodegradable polymeric doxorubicin micelles. J Control Rel 2004;96:273-283.
24. Kukowska-Latallo JF, Candido KA, Cao Z, Nigavekar SS, Majoros IJ, Thomas TP, Balogh LP, Khan MK, Baker JR, Jr. Nanoparticle targeting of anticancer drug improves therapeutic response in animal model of human epithelial cancer. Cancer Res 2005;65:5317-5324.
25. Mamot C, Drummond DC, Greiser U, Hong K, Kirpotin DB, Marks JD, Park JW. Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells. Cancer Res 2003;63:3154-3161.
26. Nielsen UB, Kirpotin DB, Pickering EM, Hong K, Park JW, Refaat Shalaby M, Shao Y, Benz CC, Marks JD. Therapeutic efficacy of anti-ErbB2 immunoliposomes targeted by a phage antibody selected for cellular endocytosis. Biochim Biophys Acta 2002;1591:109-118.
27. Nobs L, Buchegger F, Gurny R, Allemann E. Biodegradable nanoparticles for direct or two-step tumor immunotargeting. Bioconjug Chem 2006;17:139-145.
28. Ignatius AA, Claes LE. In vitro biocompatibility of bioresorbable polymers: Poly(L, D,L-lactide) and poly(L-lactide -co-glycolide). Biomaterials 1996;17:831-839.
29. Shive MS, Anderson JM. Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv Drug Deliv Rev 1997;28:5-24.
30. Keegan ME, Falcone JL, Leung TC, Saltzman WM. Biodegradable microspheres with enhanced capacity for covalently bound surface ligands. Macromolecules 2004;37:9779-9784.
31. Lavik EB, Hrkach JS, Lotan N, Nazarov R, Langer R. A simple synthetic route to the formation of a block copolymer of poly(lactic-co-glycolic acid) and polylysine for the fabrication of functionalized, degradable structures for biomedical applications. J Biomed Mater Res 2001;58:291-294.
32. Caponetti G, Hrkach JS, Kriwet B, Poh M, Lotan N, Colombo P, Langer R. Microparticles of novel branched copolymers of lactic acid and amino acids: Preparation and characterization. J Pharm Sci 1999;88:136-141.
33. Salem AK, Cannizzaro SM, Davies MC, Tendler SJ, Roberts CJ, Williams PM, Shakesheff KM. Synthesis and characterisation of a degradable poly(lactic acid)-poly(ethylene glycol) copolymer with biotinylated end groups. Biomacromolecules 2001;2:575-580.
34. Gref R, Couvreur P, Barratt G, Mysiakine E. Surface-engineered nanoparticles for multiple ligand coupling. Biomaterials 2003;24:4529-4537.
35. Tessmar JK, Mikos AG, Gopferich A. Amine-reactive biodegradable diblock copolymers. Biomacromolecules 2002;3:194-200.
36. Zheng J, Hornsby PJ. Production of microspheres with surface amino groups from blends of poly(lactide-co-glycolide) and poly(epsilon-CBZ- L-lysine) and use for encapsulation. Biotechnol Prog 1999;15:763-767.
37. Fessi H, Puisieux F, Devissaguet JP, Ammoury N, Benita S Nanocapsule formation by interfacial polymer deposition following solvent dsiplacement. Int J Pharm 1989;55:R1-R4.
38. McCarron PA, Donnelly RF, Marouf W. Celecoxib-loaded poly(D,L- lactide-co-glycolide) nanoparticles prepared using a novel and controllable combination of diffusion and emulsification steps as part of the salting-out procedure. J Microencapsul 2006;23:480-498.
39. Sehgal D, Vijay IK. A method for the high efficiency of water-soluble carbodiimide-mediated amidation. Anal Biochem 1994;218:87-91.
40. Tosi G, Rivasi F, Gandolfi F, Costantino L, Vandelli MA, Forni F. Conjugated poly(D,L-lactide-co-glycolide) for the preparation of in vivo detectable nanoparticles. Biomaterials 2005;26:4189-4195.
41. Damiani P, Bearzotti M, Cabezon MA. A validated spectrofluorometric method for the determination of celecoxib in capsules. Anal Bioanal Chem 2003;376:1141-1146.
42. Vandervoort J, Ludwig A. Biocompatible stabilizers in the preparation of PLGA nanoparticles: A factorial design study. Int J Pharm 2002;238:77-92.
43. Feng S, Huang G. Effects of emulsifiers on the controlled release of paclitaxel (Taxol) from nanospheres of biodegradable polymers. J Control Rel 2001;71:53-69.
44. Ravivarapu HB, Burton K, DeLuca PP. Polymer and microsphere blending to alter the release of a peptide from PLGA microspheres. Eur J Pharm Biopharm 2000;50:263-270.
45. Graves RA, Pamujula S, Moiseyev R, Freeman T, Bostanian LA, Mandal TK. Effect of different ratios of high and low molecular weight PLGA blend on the characteristics of pentamidine microcapsules. Int J Pharm 2004;270:251-262.